6-benzyl-4-methyl-2H-pyran-2-thione | 1434047-45-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 6-benzyl-4-methyl-2H-pyran-2-thione
• 英文别名: 6-Benzyl-4-methylpyran-2-thione；6-benzyl-4-methylpyran-2-thione
• CAS: 1434047-45-6
• 化学式: C₁₃H₁₂OS
• 分子量: 216.304
• InChiKey: CZDMPAZPNOXDFR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  41.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  6-benzyl-4-methyl-2H-pyran-2-thione 在 吡啶 、 盐酸羟胺 作用下， 生成 1-羟基-4-甲基-6-(苯甲基)-2-(1H)吡啶酮
  参考文献：
  名称：

  抑制癌症相关突变异柠檬酸脱氢酶：合成、结构-活性关系和选择性抗肿瘤活性

  摘要：

  异柠檬酸脱氢酶 1 (IDH1) 的突变常见于某些癌症，例如神经胶质瘤。与野生型 (WT) IDH1 不同，突变酶催化 α-酮戊二酸还原为d -2-羟基戊二酸 (D2HG)，从而引发癌症。几种 1-hydroxypyridin-2-one 化合物被鉴定为 IDH1(R132H) 的抑制剂。共合成了 61 种衍生物，并研究了它们的构效关系。用K i鉴定了有效的 IDH1(R132H) 抑制剂值低至 140 nM，而它们对 WT IDH1 具有弱活性或无活性。发现所选化合物对 IDH1(R132C) 的活性与其对 IDH1(R132H) 的抑制活性以及 D2HG 的细胞产生相关，R 2分别为 0.83 和 0.73。在基于细胞的模型测定中发现几种抑制剂可渗透血脑屏障，并对具有IDH1 R132H 突变的神经胶质瘤细胞表现出有效的选择性活性（EC 50 = 0.26–1.8 μM）。

  DOI：

  10.1021/jm500660f
• 作为产物：
  描述：

  6-benzyl-4-methyl-2H-pyran-2-one 在 tetraphosphorus decasulfide 作用下， 以 苯 为溶剂， 反应 5.0h， 以78%的产率得到6-benzyl-4-methyl-2H-pyran-2-thione
  参考文献：
  名称：

  抑制癌症相关突变异柠檬酸脱氢酶：合成、结构-活性关系和选择性抗肿瘤活性

  摘要：

  异柠檬酸脱氢酶 1 (IDH1) 的突变常见于某些癌症，例如神经胶质瘤。与野生型 (WT) IDH1 不同，突变酶催化 α-酮戊二酸还原为d -2-羟基戊二酸 (D2HG)，从而引发癌症。几种 1-hydroxypyridin-2-one 化合物被鉴定为 IDH1(R132H) 的抑制剂。共合成了 61 种衍生物，并研究了它们的构效关系。用K i鉴定了有效的 IDH1(R132H) 抑制剂值低至 140 nM，而它们对 WT IDH1 具有弱活性或无活性。发现所选化合物对 IDH1(R132C) 的活性与其对 IDH1(R132H) 的抑制活性以及 D2HG 的细胞产生相关，R 2分别为 0.83 和 0.73。在基于细胞的模型测定中发现几种抑制剂可渗透血脑屏障，并对具有IDH1 R132H 突变的神经胶质瘤细胞表现出有效的选择性活性（EC 50 = 0.26–1.8 μM）。

  DOI：

  10.1021/jm500660f

文献信息

• Inhibition of Cancer-Associated Mutant Isocitrate Dehydrogenases: Synthesis, Structure–Activity Relationship, and Selective Antitumor Activity
  作者：Zhen Liu、Yuan Yao、Mari Kogiso、Baisong Zheng、Lisheng Deng、Jihui J. Qiu、Shuo Dong、Hua Lv、James M. Gallo、Xiao-Nan Li、Yongcheng Song

  DOI：10.1021/jm500660f

  日期：2014.10.23

  total of 61 derivatives were synthesized, and their structure–activity relationships were investigated. Potent IDH1(R132H) inhibitors were identified with Ki values as low as 140 nM, while they possess weak or no activity against WT IDH1. Activities of selected compounds against IDH1(R132C) were found to be correlated with their inhibitory activities against IDH1(R132H), as well as cellular production

  异柠檬酸脱氢酶 1 (IDH1) 的突变常见于某些癌症，例如神经胶质瘤。与野生型 (WT) IDH1 不同，突变酶催化 α-酮戊二酸还原为d -2-羟基戊二酸 (D2HG)，从而引发癌症。几种 1-hydroxypyridin-2-one 化合物被鉴定为 IDH1(R132H) 的抑制剂。共合成了 61 种衍生物，并研究了它们的构效关系。用K i鉴定了有效的 IDH1(R132H) 抑制剂值低至 140 nM，而它们对 WT IDH1 具有弱活性或无活性。发现所选化合物对 IDH1(R132C) 的活性与其对 IDH1(R132H) 的抑制活性以及 D2HG 的细胞产生相关，R 2分别为 0.83 和 0.73。在基于细胞的模型测定中发现几种抑制剂可渗透血脑屏障，并对具有IDH1 R132H 突变的神经胶质瘤细胞表现出有效的选择性活性（EC 50 = 0.26–1.8 μM）。
• Crystallographic Investigation and Selective Inhibition of Mutant Isocitrate Dehydrogenase
  作者：Baisong Zheng、Yuan Yao、Zhen Liu、Lisheng Deng、Justin L. Anglin、Hong Jiang、B. V. Venkataram Prasad、Yongcheng Song

  DOI：10.1021/ml400036z

  日期：2013.6.13

  Mutations in isocitrate dehydrogenase (IDH), a key enzyme in the tricarboxylic acid cycle, have recently been found in similar to 75% glioma and similar to 20% acute myeloid leukemia. Different from the wild-type enzyme, mutant IDH1 catalyzes the reduction of alpha-ketoglutaric acid to D-2-hydroxyglutaric acid. Strong evidence has shown mutant IDH1 represents a novel target for this type of cancer. We found two 1-hydroxypyridin-2-one compounds that are potent inhibitors of R132H and R132C mutants with K-i values as low as 120 nM. These compounds exhibit >60-fold selectivity against wild-type IDH1 and can inhibit the production of D-2-hydroxyglutaric acid in IDH1 mutated cells, representing novel chemical Probes for cancer biology studies. We also report the first inhibitor-bound crystal structures of IDH1(R132H), showing these inhibitors have H-bond, electrostatic, and hydrophobic interactions with the mutant enzyme. Comparison with the substrate-bound IDH1 structures revealed the structural basis for the high enzyme selectivity of these compounds.
• Development of Novel <i>N</i>-hydroxypyridone Derivatives as Potential Anti-Ischemic Stroke Agents
  作者：Linghao Hu、Hongxuan Feng、Hongguang Zhang、Songda Yu、Qinyuan Zhao、Wei Wang、Fengxia Bao、Xun Ding、Jiajing Hu、Manjiong Wang、Yixiang Xu、Zengrui Wu、Xiaokang Li、Yun Tang、Fei Mao、Xiaoyan Chen、Haiyan Zhang、Jian Li

  DOI：10.1021/acs.jmedchem.9b01338

  日期：2020.2.13

  Our previous study had identified ciclopirox (CPX) as a promising lead compound for treatment of ischemic stroke. To find better neuroprotective agents, a series of N-hydroxypyridone derivatives based on CPX were designed, synthesized, and evaluated in this study. Among these derivatives, compound 11 exhibits significant neuroprotection against oxygen glucose deprivation and oxidative stress -induced injuries in neuronal cells. Moreover, compound 11 possesses good blood-brain barrier permeability and superior antioxidant capability. In addition, a complex of compound 11 with olamine-11.01a possesses good water solubility, negligible hERG inhibition, and superior metabolic stability. The in vivo experiment demonstrates that 11.01a significantly reduces brain infarction and alleviates neurological deficits in middle cerebral artery occlusion rats. Hence, compound 11.01a is identified in our research as a prospective prototype in the innovation of stroke treatment.